SLCO1B3 and prostate carcinoma: However, other notable trends were SLCO2B1 decreased expression by stage in pancreatic cancer, SLCO1B3 increased frequency by stage in prostate cancer, and SLCO1B1 decreased expression by stage in liver cancer.